Kyverna Therapeutics (KYTX) Leerink’s Global Healthcare Conference 2025 summary

Strategic vision and leadership

• Aims to be the first to launch a CAR-T therapy in autoimmune diseases, focusing on a differentiated, fully humanized CD19, CD28 construct with strong efficacy and safety profile.

• Leadership team strengthened with late-stage development and commercialization expertise; cash runway extends into 2027.

• Focused on three lead indications: stiff person syndrome (SPS), myasthenia gravis (MG), and lupus nephritis (LN), with additional pipeline opportunities in MS and systemic sclerosis.

• Strategic prioritization based on early value creation, patient impact, and alignment with financial resources.

• Plans to expand with KYV-102, a rapid whole-blood manufacturing process to improve access and reduce costs.

Clinical progress and data highlights

• Early patients in SPS, MG, and LN show transformative, durable responses beyond one year, with deep B-cell depletion and no high-grade CRS or ICANS.

• SPS pivotal study over 40% enrolled, targeting full enrollment by mid-2025; top-line results expected in H1 2026, with BLA filing planned the same year.

• MG and LN studies show similar efficacy and safety; interim MG phase 2 data and LN phase 1 data expected in H2 2024.

• KYV-102 IND filing planned for H2 2024, aiming to streamline manufacturing and broaden patient access.

• RMAT designations in SPS and MG facilitate close FDA collaboration and innovative trial designs.

Differentiation and competitive positioning

• Only CD19, CD28, fully human CAR-T in autoimmune space, enabling deep B-cell depletion and immune reset.

• Demonstrates superior efficacy in MG (MG-ADL score reductions of 6–7 points, with some patients reaching zero) compared to competitors.

• Outpatient administration anticipated due to favorable safety, increasing convenience and access.

• Commercial strategy targets academic centers where most eligible patients are treated, enabling focused launch and scale-up.

• Value proposition includes potential cost savings versus chronic therapies and improved patient outcomes.